In an interview, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.
Download to Continue Reading
Sponsored by
To sign up for our newsletter or print publications, please enter your contact information below.
